InvestWiser

Spago Nanomedical AB

SPAGONasdaq StockholmHealthcareMarket value 33 m SEK
0.04SEK −5.0%
last day · Price as of 18 November 2026

The answer first

Does Spago Nanomedical beat the market?

No, Spago Nanomedical has not beaten the market over the last year.

Spago Nanomedical−62.1%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 14% of Nordic stocks

    • Quality73
    • Value9
    • Trend11

    No. 151 of 195 in healthcare

Max for seven days

Follow Spago Nanomedical with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Spago Nanomedical

From today, at a price of 0.04 SEK. Write why you follow Spago Nanomedical, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Spago Nanomedical

Your first answer is free, no account needed.

Do you own Spago Nanomedical, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Spago Nanomedical and a few more. Free, no card.

Past year against the exchange and Super Stock
Spago Nanomedical−64.0%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Spago Nanomedical has fallen 62.1% over the past year, including dividends.
  • Overall, Spago Nanomedical ranks better than 14% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 97.3%. The price is 99.8% below its peak now.

What do analysts think of Spago Nanomedical?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

14

Quality, value and trend together. Better than 14% of Nordic stocks.

No. 151 of 195 in healthcare

Quality73
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 78 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.25
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−97.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value9
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 138 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity1.3
  • P/SPrice divided by sales577.9
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend11
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 152 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−63.5%
  • 6 months−68.0%
  • 9 months−64.9%
  • 12 months−62.1%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−59.2%
3 years, per year
−38.9%
5 years, per year
−59.3%
10 years, per year
−40.2%
Largest fall, 3 years
−97.3%
From a peak to the bottom
From the peak now
−99.8%
How far the price is from the peak
Volatility, 1 year
99.3%
How much the price swings over a year
Beta, 1 year
1.03
How much the price moves when the market moves

Return with dividends reinvested.

About Spago Nanomedical

Spago Nanomedical AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.

Spago Nanomedical AB (publ), a nanomedicine company, engages in the development projects based on a platform of polymeric materials for diagnosis and treatment of life-threatening and debilitating diseases in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment of liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of cancer. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.

See the full analysis of Spago Nanomedical.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market